Pharmacological characteristics and clinical efficacies of a novel potassium-competitive acid blocker, vonoprazan fumarate

DOI Web Site Web Site PubMed 23 References
  • Matsukawa Jun
    Gastroenterology Drug Discovery Unit, Takeda California, Inc.
  • Inatomi Nobuhiro
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
  • Nishida Haruyuki
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
  • Tsukimi Yasuhiro
    Gastroenterology Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited

Bibliographic Information

Other Title
  • 新規カリウムイオン競合型アシッドブロッカー ボノプラザンフマル酸塩の薬理学的特性と臨床効果
  • シンキ カリウムイオン キョウゴウガタ アシッドブロッカー ボノプラザンフマル サンエン ノ ヤクリガクテキ トクセイ ト リンショウ コウカ

Search this article

Abstract

<p>Proton pump inhibitors (PPIs) inhibit H+, K+-ATPase, an enzyme which is the final step of gastric acid secretion and is selectively located in the gastric parietal cells. PPIs block the enzyme in a covalent and irreversible binding manner, thus providing better efficacy than previous pharmacological agents such as antacids and histamine H2 receptor antagonists. Although PPIs have been the first-line therapeutic option for acid related diseases (ARDs), there are several limitations to their efficacy, i.e. short half-life in blood, insufficient acid suppression especially at night, necessity of repeated dosages for full action, and large variation in efficacy among patients due to CYP2C19 polymorphism. To overcome these shortcomings, we performed a high-throughput random screening using in-house chemical libraries and further lead optimization to look for the most relevant clinical candidate compounds. As the results of these researches, we discovered vonoprazan fumarate, a novel gastric acid antisecretory agent which inhibits H+, K+-ATPase in a reversible and K+-competitive manner. Vonoprazan exerted a more potent and longer lasting inhibitory effect than lansoprazole on gastric acid secretion in preclinical studies, presumably by its high accumulation profile in the gastric parietal cells. It also exhibited a rapid onset of action and prolonged inhibition of intragastric acidity in humans and showed remarkable effects on multiple ARDs including erosive esophagitis and Helicobacter pylori eradication. Vonoprazan fumarate was approved in 2014 for clinical use in Japan. Vonoprazan is a new therapeutic option which can potentially improve outcomes compared with conventional PPI-based treatments for ARDs.</p>

Journal

References(23)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top